Clinical TrialsLenz’s Phase II and Phase III studies of LNZ100 showed impressive efficacy, indicating a potential blockbuster opportunity for the product.
Market StrategyThe company's education and awareness campaign with eyecare professionals continues ahead of the potential approval, with over 50 key opinion leaders signed up as ambassadors.
PartnershipsLenz announced an exclusive license and commercialization agreement with Laboratoires Théa for LNZ100 in Canada, which is viewed as a good deal for Lenz.
Regulatory ReviewThe review of LNZ100 by the FDA continues on track, with no major or minor observations and no requests for additional data, suggesting the review is progressing smoothly.